Yuichiro Ohe

41.6k citations

561 papers · 21.9k indexed · 9 hit papers · h-index 61

Pulmonary and Respiratory Medicine top 0.02%
Oncology top 0.05%
Molecular Biology top 1%
Cancer Research top 0.2%
Epidemiology top 1%

Co-authors: Nagahiro Saijo James Chih‐Hsin Yang Yutaka Nishiwaki Tomohide Tamura Masahiro Fukuoka Yukito Ichinose Haiyi Jiang Noboru Yamamoto
Topics: Lung Cancer Treatments and Mutations (324 papers)Lung Cancer Research Studies (175 papers)Lung Cancer Diagnosis and Treatment (106 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: New England Journal of Medicine Nature Communications Journal of Clinical Oncology
Partner nations: Japan United States United Kingdom

In The Last Decade

Yuichiro Ohe

539 papers receiving 21.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2009 6.4k citations Nagahiro Saijo, Yuichiro Ohe et al. profile →
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 1.6k citations Yuichiro Ohe, Suresh S. Ramalingam et al. profile →
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

2005 606 citations Toshimi Takano, Yuichiro Ohe et al. profile →
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

2006 515 citations Yuichiro Ohe, Kaoru Kubota et al. profile →
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

2013 449 citations Takashi Seto, Makoto Nishio et al. profile →
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

2017 380 citations Suresh S. Ramalingam, Yuichiro Ohe et al. profile →
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

2020 303 citations Kōichi Goto, Yuichiro Ohe et al. profile →
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

2022 244 citations Yuichiro Ohe et al. profile →
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

2023 130 citations Juliann Chmielecki, Jhanelle E. Gray et al. Nature Communications profile →

Peers

Countries citing papers authored by Yuichiro Ohe

Since Specialization

Citations

This map shows the geographic impact of Yuichiro Ohe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuichiro Ohe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuichiro Ohe more than expected).

Fields of papers citing papers by Yuichiro Ohe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuichiro Ohe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuichiro Ohe. The network helps show where Yuichiro Ohe may publish in the future.

Co-authorship network of co-authors of Yuichiro Ohe

This figure shows the co-authorship network connecting the top 25 collaborators of Yuichiro Ohe. A scholar is included among the top collaborators of Yuichiro Ohe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuichiro Ohe. Yuichiro Ohe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nurse‐Led Screening‐Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial 2024 ·Cancer Medicine ·Yoshihisa Matsumoto,Shigeki Umemura,(unknown),Daisuke Fujisawa,Takuhiro Yamaguchi,Shunsuke Oyamada,Tempei Miyaji,(unknown),Naoko Kobayashi,Eriko Satomi,(unknown),Tatsuya Morita,Yosuke Uchitomi,Kōichi Goto,Yuichiro Ohe	1
2	Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma 2023 ·Translational Lung Cancer Research ·(unknown),Yuji Matsumoto,Jumpei Kashima,Tatsuya Imabayashi,(unknown),(unknown),Ken Masuda,Yuki Shinno,Yusuke Okuma,Tsutomu Yoshida,Yasushi Goto,Hidehito Horinouchi,Noboru Yamamoto,Takaaki Tsuchida,Yuichiro Ohe,Yasushi Yatabe	4
3	Clinicopathological characteristics and molecular analysis of lung cancer associated with ciliated muconodular papillary tumor/bronchiolar adenoma 2023 ·Pathology International ·(unknown),Noriko Motoi,Masaya Yotsukura,Yukihiro Yoshida,Kazuo Nakagawa,Shigehiro Yagishita,Masayuki Shirasawa,Tsutomu Yoshida,Kouya Shiraishi,Takashi Kohno,Yuichiro Ohe,Shun‐ichi Watanabe	2
4	Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial 2023 ·Lung Cancer ·Tsuneo Shimokawa,Hiroaki Okamoto,Ryunosuke Machida,(unknown),Yukio Hosomi,Yasuto Yoneshima,Hiroshi Tanaka,Kyoichi Okishio,(unknown),Kōichi Goto,Hiroaki Akamatsu,Kaoru Kubota,Kazuhiko Nakagawa,Hidehito Horinouchi,Masahiko Ando,Tomoko Kataoka,Yuichiro Ohe	4
5	Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC 2023 ·JTO Clinical and Research Reports ·(unknown),Tatsuya Yoshida,Shigehiro Yagishita,(unknown),Yuji Matsumoto,Yuki Shinno,Yusuke Okuma,Yasushi Goto,Hidehito Horinouchi,Noboru Yamamoto,Kazuhisa Takahashi,Noriko Motoi,Akinobu Hamada,Yuichiro Ohe	3
6	Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer 2023 ·Lung Cancer ·(unknown),Shigehiro Yagishita,(unknown),Yoshiharu Hayashi,Yuki Takeyasu,Ken Masuda,Yuki Shinno,Yusuke Okuma,Tatsuya Yoshida,Yasushi Goto,Hidehito Horinouchi,Noboru Yamamoto,Hiroshi Mukae,Yuichiro Ohe,Akinobu Hamada	1
7	Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancerbreakdown → 2023 ·Nature Communications ·Juliann Chmielecki,Jhanelle E. Gray,Ying Cheng,Yuichiro Ohe,Fumio Imamura,Byoung Chul Cho,Meng‐Chih Lin,Margarita Majem,Riyaz Shah,Yuri Rukazenkov,(unknown),Aleksandra Markovets,J. Carl Barrett,Ryan J. Hartmaier,Suresh S. Ramalingam	130
8	Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circulating extracellular vesicles 2023 ·Thoracic Cancer ·(unknown),Hidehito Horinouchi,Shigehiro Yagishita,Hirofumi Utsumi,(unknown),Daisuke Takekoshi,Saburo Ito,Hiroshi Wakui,(unknown),(unknown),Kae Okuma,Yūji Matsumoto,Yuki Shinno,Yusuke Okuma,Tatsuya Yoshida,Yasushi Goto,Noboru Yamamoto,Jun Araya,Yuichiro Ohe,Yu Fujita	2
9	Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial 2023 ·Cancer Science ·Tatsuya Yoshida,Toru Kumagai,Ryo Toyozawa,Ryohei Katayama,Makoto Nishio,Takashi Seto,Kōichi Goto,Nobuyuki Yamamoto,Yuichiro Ohe,Kentarou Kudou,(unknown),Pingkuan Zhang,Kazuhiko Nakagawa	7
10	Insulinoma-associated-1 (INSM1) expression in thymic squamous cell carcinoma 2022 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Jumpei Kashima,Taiki Hashimoto,Akihiko Yoshida,Yasushi Goto,Tetsuo Ushiku,Yuichiro Ohe,Shun‐ichi Watanabe,Yasushi Yatabe	6
11	Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy 2022 ·Cancer Science ·(unknown),Tomoyuki Naito,Hibiki Udagawa,Kōichi Goto,Taichi Miyawaki,Nobuaki Mamesaya,(unknown),Hirotsugu Kenmotsu,Tadasuke Shimokawaji,Terufumi Kato,Taiki Hakozaki,Yusuke Okuma,Masaki Nakamura,Yuko Nakayama,Hirokazu Watanabe,Masahiko Kusumoto,Yuichiro Ohe,Hidehito Horinouchi	6
12	Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression 2020 ·Clinical Cancer Research ·Azusa Tanimoto,Shingo Matsumoto,Shinji Takeuchi,Sachiko Arai,Koji Fukuda,Akihiro Nishiyama,Kiyotaka Yoh,Takaya Ikeda,Naoki Furuya,Kazumi Nishino,Yuichiro Ohe,Kōichi Goto,Seiji Yano	38
13	Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer 2020 ·European Journal of Cancer ·Masayuki Shirasawa,Tatsuya Yoshida,Yuji Matsumoto,Yuki Shinno,Yusuke Okuma,Yasushi Goto,Hidehito Horinouchi,Noboru Yamamoto,Shun‐ichi Watanabe,Yuichiro Ohe,Noriko Motoi	15
14	Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody 2020 ·Thoracic Cancer ·Shuji Murakami,Ryota Shibaki,Yuji Matsumoto,Tatsuya Yoshida,Yasushi Goto,Shintaro Kanda,Hidehito Horinouchi,Yutaka Fujiwara,Noboru Yamamoto,Yuichiro Ohe	36
15	TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X 2019 ·Molecular Cancer Therapeutics ·Kimihiro Ito,Makoto Nishio,Masanori Kato,Haruyasu Murakami,Yoshimi Aoyagi,Yuichiro Ohe,(unknown),Akihiro Hashimoto,Hirokazu Ohsawa,(unknown),Katsumasa Nonoshita,Satoru Ito,Kenichi Matsuo,Kazutaka Miyadera	10
16	Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies 2018 ·ESMO Open ·Midori Tanaka,Hidehito Horinouchi,Yasushi Goto,Shintaro Kanda,Yutaka Fujiwara,Hiroshi Nokihara,Noboru Yamamoto,Yuichiro Ohe	10
17	Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations 2018 ·ESMO Open ·Yuki Shinno,Yasushi Goto,Sho Watanabe,Jun Sato,Ryo Morita,Yuji Matsumoto,Shuji Murakami,Shintaro Kanda,Hidehito Horinouchi,Yutaka Fujiwara,Noboru Yamamoto,Yuichiro Ohe	5
18	Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation 2014 ·Clinical Cancer Research ·Tatsuya Yoshida,Genichiro Ishii,Kōichi Goto,Shinya Neri,Hiroko Hashimoto,Kiyotaka Yoh,Seiji Niho,Shigeki Umemura,Shingo Matsumoto,Hironobu Ohmatsu,Shinsuke Iida,Akio Niimi,Kanji Nagai,Yuichiro Ohe,Atsushi Ochiai	102
19	Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma 2007 ·Clinical Cancer Research ·Tetsuya Okano,Tadashi Kondo,Kiyonaga Fujii,Toshihide Nishimura,Toshimi Takano,Yuichiro Ohe,Koji Tsuta,Yoshihiro Matsuno,Akihiko Gemma,(unknown),Shoji Kudoh,Setsuo Hirohashi	49
20	In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. 1989 ·PubMed ·Yuichiro Ohe,Kazuhiko Nakagawa,Yasuhiro Fujiwara,Yasutsuna Sasaki,K Minato,(unknown),Shingo Niimi,Naoya Horichi,(unknown),Nagahiro Saijo	42

About Yuichiro Ohe

Yuichiro Ohe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 561 papers that have together received 21.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (324 papers), Lung Cancer Research Studies (175 papers) and Lung Cancer Diagnosis and Treatment (106 papers). The work is most often cited by research in Oncology (14.4k citations), Pulmonary and Respiratory Medicine (14.9k citations) and Cancer Research (3.9k citations). Yuichiro Ohe has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Nagahiro Saijo, James Chih‐Hsin Yang, Yutaka Nishiwaki, Tomohide Tamura, Masahiro Fukuoka, Yukito Ichinose, Haiyi Jiang, Noboru Yamamoto, Tony Mok and Emma Duffield. Their work appears in journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact